Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABCE1
REST API REST API
Homo sapiens
ABCE1 is differentially expressed in 304 experiments: 104 organism parts: blood, bone marrow, ... (102 more);, 207 disease states: normal, glioblastoma, ... (205 more);, 93 cell types 324 cell lines 40 compound treatments and 71 other conditions.
Synonyms RNASELI, RNASEL1, RLI, RNS4I, OABP
Orthologs F1P0C9_CHICK (Gallus gallus)   F6YJN3_CIOIN (Ciona intestinalis)   abce1 (Danio rerio)   A4IFE6_BOVIN (Bos taurus)   Abce1 (Rattus norvegicus)   RLI1 (Saccharomyces cerevisiae)   Abce1 (Mus musculus)   pix (Drosophila melanogaster)   abce1 (Xenopus laevis)   ABCE1 (Canis familiaris)   (Compare orthologs)
InterPro Term ATPase_AAA+_core, ABC_transporter-like, ABC_E, RNaseL-inhib_metal-bd_dom, 4Fe4S-bd_dom
Gene Ontology Term cytoplasm, nucleoside-triphosphatase activity, ATPase activity, ribonuclease inhibitor activity, metal ion binding, 4 iron, 4 sulfur cluster binding, ATP binding, electron carrier activity, iron-sulfur cluster binding, nucleotide binding, mitochondrion, response to virus, RNA catabolic process, interspecies interaction between organisms
UniProt Accession D6R9I9, D6RGF4, P61221
Search EB-eye ENSG00000164163
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SNU16
2
E-MTAB-37, E-GEOD-15460
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-37, E-MTAB-62
H820
1
E-MTAB-62
SJRH30
1
E-MTAB-37
318 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-13909, ... (43 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-GEOD-1460
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
endothelial cell
1
2
E-GEOD-3920, E-GEOD-3998, E-GEOD-19240
87 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-MEXP-2280, E-MTAB-62, ... (64 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-GEOD-19067
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
colorectal adenocarcinoma
2
E-MTAB-62, E-AFMX-5
osteosarcoma
2
E-MTAB-62, E-MTAB-37
201 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
1
2
E-TABM-868, E-GEOD-3720, E-MEXP-1958
transforming growth factor beta
1
E-GEOD-1724
camptothecin
1
E-GEOD-1417
control - interferon-gamma
1
E-GEOD-7216
mercaptopurine, methotrexate
1
E-GEOD-412
epidermal growth factor
1
E-GEOD-6462
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MEXP-958, E-MEXP-1082, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20504, E-GEOD-9764, E-GEOD-837, E-TABM-440, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-19703, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.425 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM